Results 191 to 200 of about 64,002 (290)

Aliphatic Poly(Carbonate)s with Acid Responsive Release Mechanisms for Micellar Anti‐Tumor Drug Delivery

Macromolecular Rapid Communications, EarlyView.
Micellar systems based on biodegradable aliphatic polycarbonates and acid‐responsive triggers enhance drug solubility, stability, and tumor‐selective release. This review covers micelles with acid‐cleavable drug linkages and those that disassemble via acid‐sensitive functionalities.
Adrian V. Hauck, Lutz Nuhn
wiley   +1 more source

Twisted Allenyl-Pyridocyclophanes by Templated Cyclooligomerization: Chiral Cavities for Precision Molecular Recognition. [PDF]

JACS Au
Álvarez-García J, Cid MM.
europepmc   +1 more source

Trends in spectral parameters and nephelauxetic ratio values for some lanthanoid(III)-catechol complexes

, 2002
Rashmi Singhai, V. K. Tiwari, M. C. Saxena   +2 more
openalex   +2 more sources

Comparative Analysis of the Incidence, Prevalence, and Survival of 8 Types of Parkinsonism in a Population‐Based Study with 367 Million Person Years of Observation over 21 Years

Movement Disorders Clinical Practice, EarlyView.
Abstract Background Findings are contradictory regarding changes in the incidence and prevalence of Parkinson's disease (PD) over time; data for other parkinsonian disorders are rare. Objectives To analyze temporal trends in the incidence and prevalence of eight parkinsonisms (PD, MSA, PSP, CBS, DLB, vascular parkinsonism, drug‐induced parkinsonism ...
Sacha E. Gandhi, Katherine A. Grosset, Prasanth A. Iruthayaraj, Romel Gravesande, Lance Lee, Cathal Doyle, Yoav Ben‐Shlomo, Donald G. Grosset   +7 more
wiley   +1 more source

Editorial: Catechol and Polyphenol Chemistry for Smart Polymers

Frontiers in Chemistry, 2019
Bruce P. Lee, Henrik Birkedal, Haeshin Lee   +2 more
doaj   +1 more source

Movement Disorders Associated with 22q11.2 Microdeletion: A Scoping Review

Movement Disorders Clinical Practice, EarlyView.
Abstract Background Movement disorders have recently emerged as important neurologic manifestations of the 22q11.2 microdeletion that affects nearly one in every 2000 live births. Objective We aimed to map the existing evidence regarding the spectrum, diagnosis and treatment, and etiopathogenesis of movement disorders associated with 22q11.2 ...
Nikolai Gil D. Reyes, Daniel G. Di Luca, Connie Marras, Erik Boot, Ryan K.C. Yuen, Anthony E. Lang, Anne S. Bassett   +6 more
wiley   +1 more source

Cellular Upcycling of Polyethylene Terephthalate (PET) With an Engineered Human Saliva Metagenomic PET Hydrolase. [PDF]

ChemSusChem
Amornloetwattana R, Eiamthong B, Meesawat P, Bunkum P, Royer B, Zeballos N, Valenzuela-Ortega M, Robinson RC, Wallace S, Uttamapinant C.   +9 more
europepmc   +1 more source

Considerations for Initiation and Maintenance of Foslevodopa/Foscarbidopa for Advanced Parkinson's Disease

Movement Disorders Clinical Practice, EarlyView.
Abstract Background As Parkinson's disease (PD) progresses, motor fluctuations become increasingly difficult to manage with oral medications. Foslevodopa/foscarbidopa (LDp/CDp), delivered as a continuous 24‐h/day subcutaneous infusion, offers continuous levodopa delivery and stable plasma levodopa levels that reduce motor fluctuations. LDp/CDp has been
K. Ray Chaudhuri, Bruno Bergmans, Eric Freire‐Alvarez, Lucie Hopes, Drew S. Kern, Robert S. Kirsner, Giulia Lazzeri, Pedro Mendes‐Bastos, Noriko Nishikawa, Per Odin, Karolina Poplawska‐Domaszewicz, Rajesh Pahwa, Yuval Ramot, Klaus Seppi, Tobias Warnecke, Robert Wiggins, Megha B. Shah, Pavnit Kukreja, Bjoern Fritz, Koray Onuk, Stuart H. Isaacson   +20 more
wiley   +1 more source

The Redox Properties of Polyphenols and Their Role in ROS Generation for Biomedical Applications. [PDF]

Angew Chem Int Ed Engl
Bolaños-Cardet J, Pepió-Tárrega B, Saiz-Poseu J, López-Moral A, Ullah F, Yuste VJ, Ruiz-Molina D, Suárez-García S.   +7 more
europepmc   +1 more source

Continuous Subcutaneous Versus Intestinal Levodopa Infusion for Parkinson's Disease: A Real‐World, Monocentric, Observational Study and Critical Review

Movement Disorders Clinical Practice, EarlyView.
Abstract Background Subcutaneous foslevodopa‐foscarbidopa (SCFF) is a novel, non‐surgical dopaminergic infusion therapy for better controlling motor fluctuations in advanced Parkinson's disease (PD). However, there are scarce real‐world data on efficacy, adverse events and comparisons with other infusion strategies. Objectives Here, we aimed to provide
Johannes Hartig, Lennert Sitzmann, Doreen Hartenstein, Marion Labisch, Chi Wang Ip, Jens Volkmann, Christine Daniels   +6 more
wiley   +1 more source